AstraZeneca Pharma India Reports 30% Revenue Growth in Q1 FY27; PAT Falls 32%; Check Details

On Monday, Indian equity benchmark indices traded higher, with the benchmark Nifty 50 index rising 13.15 points, or 0.05 per cent, to 24,583.80. Amid the positive market movement, AstraZeneca Pharma India share price declined 1.25 per cent to Rs 8,090, despite the company reporting a 30 per cent YoY increase in total revenue from operations for the quarter ended June 30, 2026.

AstraZeneca Pharma India Q1 FY27 Results

AstraZeneca Pharma India reported revenue from operations of Rs 682.79 crore in Q1 FY27, compared with Rs 526.31 crore in the corresponding quarter of the previous year, registering a growth of approximately 30 per cent. Profit before exceptional items and tax stood at Rs 50.99 crore, compared with Rs 75.06 crore in Q1 FY26.

Profit after tax stood at Rs 37.93 crore during Q1 FY27, compared with Rs 55.83 crore in the year-ago quarter. This represents a decline of approximately 32 per cent YoY. The company reported an EPS of Rs 15.17 per share for the quarter.

Therapy Areas Report Strong Growth

The company's Oncology business generated revenue of Rs 464.9 crore, registering 26 per cent growth compared with Q1 FY26. Biopharmaceuticals, covering CVRM, R&I and V&I, reported revenue of Rs 161.9 crore, up 36 per cent YoY. Meanwhile, the Rare Diseases segment recorded revenue of Rs 14.4 crore, representing a significant increase compared with the year-ago period.

Key Regulatory Approvals

During the quarter, AstraZeneca Pharma India received regulatory approval for acalabrutinib in combination with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma. The company also received approval for acalabrutinib in combination with bendamustine and rituximab for certain previously untreated mantle cell lymphoma patients.

The company also received regulatory approval for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Also Read - Japanese Company to Invest Rs 180 Crore in This Multibagger Small-Cap Industrial Products Company; Check Details

Strategic Initiatives

AstraZeneca Pharma India signed an MoU with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities. The initiative is expected to cover 20 public health facilities across urban and rural areas and includes training and upskilling of healthcare professionals.

The company also launched K+ Connect, a pan-India initiative focused on hyperkalaemia management among patients with heart failure and chronic kidney disease. In addition, it launched India Coronary Conquest 2026 in collaboration with STEMI India to support capability building in advanced cardiovascular care.

Management Commentary

Bhavana Agrawal, Chief Financial Officer and Director of AstraZeneca Pharma India, said the company delivered 30 per cent growth in the first quarter, taking revenue to Rs 682.8 crore. She highlighted the company's track record of consistent double-digit growth over the last five years and said the focus remains on strategic investments supporting sustainable long-term value creation.

Praveen Rao Akkinepally, Country President and Managing Director, said the first-quarter performance reflected the strength of the company's portfolio and its focus on expanding access to medicines in India.

About AstraZeneca Pharma India

AstraZeneca Pharma India Limited is the listed operating company of AstraZeneca in India. It is a science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines across Oncology, Biopharmaceuticals and Rare Disease. The company has more than 600 employees across India and focuses on expanding access to differentiated medicines through commercial execution and partnerships across the healthcare ecosystem.

What do you think about AstraZeneca Pharma India's Q1 FY27 performance and 30 per cent revenue growth? Share your thoughts in the comments section.
Disclaimer: The article is for informational purposes only and not investment advice.